Research programme: cancer therepeutics - Karma Biotechnologies
Latest Information Update: 17 Nov 2023
At a glance
- Originator Karma Biotechnologies
- Class Antineoplastics; Cytokines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Colorectal cancer; Solid tumours
Most Recent Events
- 04 Oct 2023 Preclinical trials in Colorectal cancer in USA (unspecified route) (Karma Biotechnologies pipeline, October 2023)
- 04 Oct 2023 Preclinical trials in Solid tumours in USA (unspecified route) (Karma Biotechnologies pipeline, October 2023)